Altana (Germany) relies on overseas sales:
This article was originally published in Clinica
Executive Summary
Altana (Germany) has reported a "satisfactory" fiscal 1994, with sales rising 3% to DM 2,844 million ($1,860 million). The pharmaceuticals division, which includes diagnostics manufacturers Cambridge Life Sciences (UK) and Byk Gulden (Germany), saw turnover rise 5% to DM 1,409 million. Domestic sales by the division rose 3% to DM 658 million and overseas sales were up 7% at DM 751 million.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.